It is really way too early to say '113 is a better drug since the data thus far been small. And, what IF '113 has no effect in EGFR patients, or it cannot be dosed high enough to get a good thera-window?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.